Tee Labs Incubated：Innostellar Biotherapeutics Completes Series B+ Funding to Advance Gene Therapy R&D and Industrialization
June 11 – Gene therapy innovator Innostellar Biotherapeutics Co.,Ltd announced the completion of its Series B+ funding round, led by Shanghai Healthcare Capital with participation from existing shareholder United Capital Investment.
Founded in 2020, Innostellar Biotherapeutics focuses on developing and manufacturing innovative gene therapies. The company has established a scalable, GMP-compliant AAV manufacturing platform capable of producing high-yield, quality-controlled gene therapies at reduced costs. This funding will accelerate R&D and industrialization of its gene therapy pipeline. Currently advancing five clinical candidates, Innostellar Biotherapeutics leads China in initiating gene therapy clinical trials for three blinding eye diseases with three active INDs:
LX101: Phase III trial for RPE65 mutation-associated inherited retinal dystrophy
LX102: Phase II trial for wet age-related macular degeneration (wAMD)
LX103: Completed 6-patient IIT for X-linked retinoschisis with promising safety/efficacy
With years of expertise in ocular genetic/chronic diseases, Innostellar Biotherapeutics has built a robust pipeline and industrialization foundation. The company collaborates closely with leading clinical scientists globally to enhance innovation efficiency and accelerate patient access.
Dr. Wang Fenghua, Founder & CEO:
“We appreciate Shanghai Healthcare Capital and United Capital’s endorsement. This funding will strengthen our gene therapy R&D and manufacturing capabilities, accelerating clinical development. Committed to technological innovation, we aim to deliver efficient, safe, and affordable treatments – making rare diseases visible and restoring health to patients.”
Liu Dawei, President, Shanghai Healthcare Capital:
“CGT therapies show broad potential across rare and common diseases. China’s clinical translation advantages position it for global competitiveness in this space – a key focus for our fund. Leveraging Shanghai General Hospital’s (Shanghai Gene Therapy Clinical Research Center) ophthalmic expertise,Innostellar Biotherapeutics has achieved multiple ‘China-first’ clinical milestones. Their lead wAMD program pioneers gene therapy for common ophthalmic conditions affecting millions, demonstrating leading progress and excellent data. We’ll fully support their domestic development and global expansion.”
Shen Siyu, GM of Investment Division III, United Capital:
“Our global biopharma investments remain patient-centric and clinically driven. Innostellar Biotherapeutics scientific rigor, clinical expertise, and execution efficiency have developed transformative gene therapies – bringing new hope to blinding eye diseases. Their pipeline leads in China with exceptional data, notably a 0% rescue therapy rate in wAMD treatment, outperforming global competitors. Recognizing the protracted, high-risk nature of gene therapy development, we commit to long-term support to deliver these vision-restoring therapies to patients.”
About Tee Labs
Tee Labs is an industrial incubator, wholly-owned and independently operated by TF Capital, dedicated to advancing pioneering medical fields such as new drug discovery, diagnostics, and personalized medicine that incorporate artificial intelligence and digital solutions. Tee Labs provides comprehensive support—including R&D facilities, corporate services, supply chain integration, and financial backing—to deeply empower entrepreneurial teams and accelerate their R&D progress. The laboratories are equipped with basic, general-purpose experimental equipment and shared equipment platforms, significantly shortening the setup phase for startups in terms of facilities and equipment, allowing them to focus on their core R&D work.